drugset / Trial / NCT01945957
Brain Imaging of Intranasal Oxytocin Treatment in Autism
Phase 1
Completed
33 enrolled
University of North Carolina, Chapel Hill
Duke University · collabEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedParallel-groupTriple-blindOther
Summary
This is a 4 part study: Phase 1a. -functional magnetic resonance imaging (fMRI) ( with oxytocin 24 IU vs. placebo = oxytocin 0 IU) - funded by grant #U54 HD079124-01, Phase 1b-eye-tracking(oxytocin 24 IU vs. placebo = oxytocin 0 IU), Phase 2a. fMRI (oxytocin 8 IU vs. oxytocin 40IU), Phase 2b. -eye-tracking (oxytocin 8IU vs. oxytocin 40IU). Time course of effect will also be assessed within session.
Timeline
- Start
- 2014-09
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 8 iu | Intranasal |
| Subject | Oxytocin | Peptide | 24 iu | Intranasal |
| Subject | Oxytocin | Peptide | 40 iu | Intranasal |